Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down – Time to Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE) gapped down before the market opened on Wednesday . The stock had previously closed at $49.00, but opened at $40.00. Maze Therapeutics shares last traded at $31.0950, with a volume of 3,256,365 shares changing hands.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Maze announced positive topline Phase 2 HORIZON results for oral APOL1 inhibitor MZE829 showing a 35.6% mean uACR reduction in the broad AMKD population at week 12, a 61.8% mean uACR reduction in the FSGS subgroup, strong responses in non‑diabetic patients, a favorable tolerability profile, and plans to advance MZE829 into a pivotal program. This clinical proof‑of‑concept is the primary driver of the earlier rally. Phase 2 HORIZON topline release
• Positive Sentiment: Management added Neil Kumar (founder/CEO of BridgeBio) to the board and flagged two Phase 2 PoC trials for MZE782 (PKU and CKD) expected to start in 2026 — governance and pipeline expansion that investors typically view as supportive of program execution. Board appointment article
• Positive Sentiment: Maze reports a strong cash position (~$360M) with management projecting runway into 2028, reducing near‑term financing risk as they advance MZE829 toward a pivotal program. Financial results & highlights
• Neutral Sentiment: Maze is hosting an investor conference call and webcast (today) to discuss the HORIZON data and next steps — a convening that could add clarity and move the stock depending on management’s pivotal plan details and timeline. Conference call notice
• Neutral Sentiment: Short‑interest data published for March appears to be erroneous or reports no meaningful short position (entries show zero/NaN), so there’s no clear short‑squeeze signal detectable from those items. (Monitor updated short interest filings for accuracy.)
• Negative Sentiment: Maze reported Q4/2025 results showing a GAAP loss per share (EPS of -$0.65) — typical for a clinical‑stage biotech but a reminder of ongoing R&D expense; some of the intraday selling likely reflects profit‑taking and digestion of the company’s cash burn profile despite runway commentary. Earnings release

Wall Street Analysts Forecast Growth

MAZE has been the subject of several analyst reports. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $64.11.

Maze Therapeutics Stock Down 31.3%

The stock has a fifty day simple moving average of $46.16 and a 200 day simple moving average of $37.60. The firm has a market capitalization of $1.62 billion, a P/E ratio of -1.63 and a beta of 4.47.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Friday, March 20th. The shares were sold at an average price of $49.10, for a total value of $736,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the sale, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. The trade was a 27.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 245,000 shares of company stock worth $10,504,792 over the last quarter.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the 4th quarter valued at approximately $145,000. Invesco Ltd. grew its holdings in shares of Maze Therapeutics by 1.5% in the fourth quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock valued at $5,553,000 after purchasing an additional 1,971 shares in the last quarter. ADAR1 Capital Management LLC increased its position in Maze Therapeutics by 589.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock worth $7,438,000 after purchasing an additional 153,487 shares during the last quarter. XTX Topco Ltd increased its position in Maze Therapeutics by 22.9% in the fourth quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock worth $1,368,000 after purchasing an additional 6,154 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Maze Therapeutics during the fourth quarter valued at $2,536,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.